

# Checklist for Prescribers:

Individual Label

## Initiation of TRUVADA® for Pre-exposure Prophylaxis (PrEP)

**Instructions: Complete checklist at each visit and file in individual's medical record.**

I have completed the following prior to prescribing TRUVADA for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking TRUVADA for a PrEP indication:

- Completed high risk evaluation of uninfected individual
- Confirmed a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: TRUVADA for a PrEP indication is contraindicated in individuals with unknown HIV-1 status or who are HIV-1 positive)
- Discussed known safety risks with use of TRUVADA for a PrEP indication
- Counseled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking TRUVADA for PrEP to confirm HIV-1 status
- Discussed the importance of discontinuing TRUVADA for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants
- Counseled on the importance of adherence to daily dosing schedule
- Counselled that TRUVADA for a PrEP indication should be used only as part of a comprehensive prevention strategy
- Educated on practicing safer sex consistently and using condoms correctly
- Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)
- Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission
- Performed HBV screening test. Offered HBV vaccination as appropriate
- Confirmed creatinine clearance (CrCl)  $\geq 60$  mL/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use
- Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or hepatitis B medications
- Provided education on where information about PrEP can be accessed
- Discussed potential adverse events and side effects
- Reviewed the TRUVADA Medication Guide with the uninfected individual at high risk
- Evaluated risk/benefit for women who may be pregnant or may want to become pregnant

**Truvada®**

200 mg emtricitabine · tenofovir disoproxil fumarate 300 mg

 GILEAD

© 2012 Gilead Sciences, Inc.  
All rights reserved. PP13650 07/12